Partnership and or Licensing, page-17

ViiV seems to have included BIT225 in many patents.

The patents are put into combination with there drugs.

I believe this is a sign of ViiV understands the value of Biotron's technology
and our library of compounds.

These companies are well aware of Biotrons latest data in abstract at the Aids 2020 virtual conference. Biotron BIT225 has fill the gaps they needed too and IMO a partnership and or licensing agreement is on the cards.

Combinations and uses and treatments thereof

WO EP US EP3664895A1 Mark I. Cockett VIIV Healthcare Company

Priority 2017-08-09 • Filed 2018-08-02 • Published 2020-06-17

(22) other drugs for treating HIV chosen from: REP 9, cytolin, CYT-107, alisporivir, BanLec, MK-8507, AG-1105, TR-452, MK-8591, REP 9, NOV-205, IND-02, metenkefalin, PGN-007, Acemannan, Gamimune, SCY-635, prolastin, 1,5-dicaffeoylquinic acid, BIT-225, RPI-MN, VSSP, Hlviral, IM0-3100, SB-728-T, RPI- …

Combinations and uses and treatments thereof

WO EP EP3664896A1 Mark I. Cockett VIIV Healthcare Company

Priority 2017-08-09 • Filed 2018-08-02 • Published 2020-06-17

(22) other drugs for treating HIV chosen from: REP 9, cytolin, CYT-107, alisporivir, BanLec, MK-8507, AG-1105, TR-452, MK-8591, REP 9, NOV-205, IND-02, metenkefalin, PGN-007, Acemannan, Gamimune, SCY-635, prolastin, 1,5-dicaffeoylquinic acid, BIT-225, RPI-MN, VSSP, Hlviral, IM0-3100, SB-728-T, RPI- …

Combination drug therapy

WO EP US WO2019016679A1 Trevor R. SCOTT Viiv Healthcare Company

Priority 2017-07-18 • Filed 2018-07-16 • Published 2019-01-24

(22) other drugs for treating HIV chosen from: REP 9, cytolin, CYT-107, alisporivir, BanLec, MK-8507, AG-1 105, TR-452, MK-8591, REP 9, NOV-205, IND-02, metenkefalin, PGN-007, Acemannan, Gamimune, SCY-635, prolastin, 1,5-dicaffeoylquinic acid, BIT-225, RPI-MN, VSSP, Hlviral, IM0-3100, SB-728-T, RPI …